Terms: = Prostate cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
17850 results:
1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract] [Full Text] [Related]
2. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
Lin Y; Xu G; Li L; Xiang J; Zhai L
Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
[TBL] [Abstract] [Full Text] [Related]
3. First in vitro measurement of VHEE relative biological effectiveness (RBE) in lung and prostate cancer cells using the ARES linac at DESY.
Wanstall HC; Burkart F; Dinter H; Kellermeier M; Kuropka W; Mayet F; Vinatier T; Santina E; Chadwick AL; Merchant MJ; Henthorn NT; Köpke M; Stacey B; Jaster-Merz S; Jones RM
Sci Rep; 2024 May; 14(1):10957. PubMed ID: 38740830
[TBL] [Abstract] [Full Text] [Related]
4. Increasing the radiation-induced cytotoxicity by silver nanoparticles and docetaxel in prostate cancer cells.
Hatami Zharabad S; Mohammadian M; Zohdi Aghdam R; Hassanzadeh Dizaj M; Behrouzkia Z
Mol Biol Rep; 2024 May; 51(1):633. PubMed ID: 38724835
[TBL] [Abstract] [Full Text] [Related]
5. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract] [Full Text] [Related]
6. Identifying risk factors for hypoxemia during emergence from anesthesia in patients undergoing robot-assisted laparoscopic radical prostatectomy.
Zhang Q; Zhu L; Yuan S; Lu S; Zhang X
J Robot Surg; 2024 May; 18(1):200. PubMed ID: 38713381
[TBL] [Abstract] [Full Text] [Related]
7. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract] [Full Text] [Related]
8. A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence.
Liu C; Chang Z; Chen K; Xue Q; Shu B; Wei Z; Zhou X; Guo L; Zhang Y; Pan Y; Cao Q; Liang H; Sun Q; Zhang X
J Nanobiotechnology; 2024 May; 22(1):224. PubMed ID: 38702709
[TBL] [Abstract] [Full Text] [Related]
9. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy.
Lokeshwar SD; Ali A; Weiss TR; Reynolds J; Shuch BM; Ferencz T; Kyriakides TC; Mehal WZ; Brito J; Renzulli J; Leapman MS
BMC Urol; 2024 May; 24(1):102. PubMed ID: 38702664
[TBL] [Abstract] [Full Text] [Related]
10. treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
Mathew Thomas V; Jo Y; Tripathi N; Roy S; Chigarira B; Narang A; Gebrael G; Hage Chehade C; Sayegh N; Galarza Fortuna G; Ji R; Campbell P; Li H; Agarwal N; Gupta S; Swami U
JAMA Netw Open; 2024 May; 7(5):e249417. PubMed ID: 38696168
[TBL] [Abstract] [Full Text] [Related]
11. Dual-mode fluorescence and colorimetric smartphone-based sensing platform with oxidation-induced self-assembled nanoflowers for sarcosine detection.
Liu P; Sun Q; Gai Z; Yang F; Yang Y
Anal Chim Acta; 2024 Jun; 1306():342586. PubMed ID: 38692787
[TBL] [Abstract] [Full Text] [Related]
12. Plant-Based Diets and Disease Progression in Men With prostate cancer.
Liu VN; Van Blarigan EL; Zhang L; Graff RE; Loeb S; Langlais CS; Cowan JE; Carroll PR; Chan JM; Kenfield SA
JAMA Netw Open; 2024 May; 7(5):e249053. PubMed ID: 38691361
[TBL] [Abstract] [Full Text] [Related]
13. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
[TBL] [Abstract] [Full Text] [Related]
14. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of treatment Response.
Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
[TBL] [Abstract] [Full Text] [Related]
15. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
16. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
17. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
18. Predictive value of magnetic resonance imaging diffusion parameters using artificial intelligence in low-and intermediate-risk prostate cancer patients treated with stereotactic ablative radiotherapy: A pilot study.
Kedves A; Akay M; Akay Y; Kisiván K; Glavák C; Miovecz Á; Schiffer Á; Kisander Z; Lőrincz A; Szőke A; Sánta B; Freihat O; Sipos D; Kovács Á; Lakosi F
Radiography (Lond); 2024 May; 30(3):986-994. PubMed ID: 38678978
[TBL] [Abstract] [Full Text] [Related]
19. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
20. treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan.
Nishimoto H; Inui A; Mifune Y; Yamaura K; Bando Y; Okamura Y; Hara T; Terakawa T; Kuroda R
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674197
[No Abstract] [Full Text] [Related]
[Next]
